Home / Intelligence / Webinars / Goodbye Humira, Hello Future
Available On Demand
Biosimilar versions of adalimumab have launched in the U.S., ending blockbuster therapy Humira’s lengthy market exclusivity and long-running commercial success. In parallel, in the creation of the Inflation Reduction Act (IRA), the U.S. joins Europe and other major markets in constraining the opportunity for medicines during their market exclusivity window. The life sciences industry now seeks to understand how the vision for commercial success will evolve while in parallel navigating new artificial intelligence (AI) and other general-purpose technologies (GPTs) technologies that present both massive opportunities and further uncertainties.
Join Maximilian Hunt, a Partner in Trinity Life Sciences’ Evidence, Value, Access and Pricing (EVAP) practice, as he moderates a lively panel discussion around a series of provocative topics related to our latest blog post “The Last Mega Blockbuster Drug: Goodbye Humira, Hello Future” to help you evolve your thinking around the future of the life sciences industry.
Key Webinar Topics
- How does the lifecycle of Humira compare with blockbusters past and future?
- How is the landscape evolving after the introduction of the Inflation Reduction Act in 2022?
- How can pharma leverage emerging technologies such as AI and other GPTs?
Featuring
Maximilian Hunt
Partner,
Value, Access & Pricing
Andy Wong
Partner,
Strategic Advisory
Robert Albarano
Managing Director
Complete the form below to view the on-demand webinar.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
This webinar will be hosted within the ON24 platform, which requires the usage of Javascript and Cookies. Please see ON24’s Privacy Policy for more information.
Related Intelligence
Webinars
Part D in Peril: The Inconvenient Math of IRA Part D Redesign
August 14, 2025 | 12:00 – 12:45 PM ET
Medicare Part D is undergoing its most significant transformation in decades largely driven by the IRA. What does this mean for pharmaceutical manufacturers? Join us for an engaging discussion with Max Hunt, Partner at Trinity, and special guest Dan Simenc, clinical and actuarial expert at Milliman, as they provide perspectives on recent developments and future expectations for Medicare Part D and Medicare Advantage.
Sign Up Now
Blog
Joint Clinical Assessment in the EU: What Life Sciences Companies Need to Know
March 2025 marked a pivotal moment for pharmaceutical and biotech companies operating in the European Union (EU) as the first two molecules began to proceed through the Joint Clinical Assessment (JCA) process. At a recent seminar hosted by Trinity Life Sciences, stakeholders gathered to explore the implications of this new regulatory framework and how to […]
Read More
Blog
Pricing and Access in Germany: Innovation and Strong Evidence Rewarded
Germany’s Medical Research Act (Medizinforschungsgesetz or MFG), which came into force on October 30, 2024, is a major legislative reform aimed at strengthening Germany’s position as an attractive environment for medical innovation and pharmaceutical development. The act provides for confidential negotiated drug pricing, incentives for local clinical trials, simplified clinical trial approvals and harmonization of […]
Read More